Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo-Reference-Cited by-同舟云学术

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Published:2020-01-14 Issue:3 Volume:14 Page:645-656
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Perrone Emanuele¹²^ORCID,Manara Paola¹,Lopez Salvatore¹³,Bellone Stefania¹,Bonazzoli Elena¹^ORCID,Manzano Aranzazu¹,Zammataro Luca¹,Bianchi Anna¹,Zeybek Burak¹,Buza Natalia⁴,Tymon‐Rosario Joan¹,Altwerger Gary¹,Han Chanhee¹,Menderes Gulden¹,Huang Gloria S.¹,Ratner Elena¹,Silasi Dan‐Arin¹,Azodi Masoud¹,Hui Pei⁴,Schwartz Peter E.¹,Scambia Giovanni²,Santin Alessandro D.¹^ORCID

Affiliation:

1. Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine New Haven CT USA

2. Department Woman and Child Health Sciences Universita' Cattolica del Sacro Cuore Rome Italy

3. Department of Experimental and Clinical Medicine Magna Graecia University Catanzaro Italy

4. Department of Pathology Yale University School of Medicine New Haven CT USA

Funder

Fondazione Guido Berlucchi

Honorable Tina Brozman Foundation

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology